Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (112542)	8/25/2000 5:47:33 PM
From: Peace	Read Replies (1) \| Respond to of 120523

Hi Jenna, I read the actual Lehman report. They said that the FDA approvals were good news but there was also some adverse news regarding patent litigation with Smithkline. Because of the adverse news they said that shares may come under pressure and they recommend buying if investors overreact. They do maintain a Buy rating with a $75 target. Peace